Saturday, September 5, 2026
ExploreSearch
Via News
MarketIndexes

Nikkei 225 Over 5% Up In The Last 10 Sessions

ViaNews Editorial Team

October 2, 2024

Nikkei 225 Over 5% Up In The Last 10 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 5.32% for the last 10 sessions. At 21:08 EST on Tuesday, 1 October, Nikkei 225 (N225) is $38,128.43.

Concerning Nikkei 225's yearly highs and lows, it's 25.06% up from its 52-week low and 10.13% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was a positive 0.50%, a negative 0.01%, and a positive 1.72%, respectively.

Nikkei 225's highest amplitude of average volatility was 3.02% (last week), 1.61% (last month), and 1.72% (last quarter), respectively.

More news about Nikkei 225 (N225).

Categories

MarketIndexes

Tags

IndexWorld IndicesIndicesN225Nikkei 225Price UpINDICES Price UpIndex Nowintelligent
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com